Daniel Reker and Katherine Franz Receive Wellcome Leap Funding to Develop Safer Antibiotics
The Duke team will use AI to make drugs more precise to avoid damage to the microbiome
The Duke team will use AI to make drugs more precise to avoid damage to the microbiome
New research shows that pooling data across patients can make brain-to-speech computer interfaces faster and easier to deploy
Michael Rubinstein will help lead the Duke-led research center that explores the science of polymer networks: long, repeating molecules found in a broad range of materials and products from trees to tires to plastics.
Amanda Randles's HARVEY platform leverages supercomputing, physics-based simulations,and wearable device data to monitor real-time hemodynamics and spot heart failure early.
Every day, AI tools get more capable, and deployment is outpacing our understanding of what they get wrong. Duke Engineering Dean Jerry Lynch connects with three Duke University experts to break down where that gap is already showing up: in cybersecurity, in the everyday AI tools people use to get advice, and in healthcare.
Sharon Gerecht's laboratory has constructed an in vitro model to study the inner blood–retina barrier.
New data-driven approach could enhance results for the quickly growing $130 billion probiotics and prebiotics industry.
Using a database of over 140 million full body poses, Dunn aims to identify similar behaviors across different animal models of autism
Tatiana Segura's lab has developed an injectable biomaterial that helps transform the cavity left behind after a stroke caused by a blood clot into an environment more supportive of repair.
Delivered more than 24 hours after a stroke in mice, the biomaterial promoted vascular repair, neural remodeling and improved motor performance
A team of students in Duke's Data+ Program is spending the summer building virtual models to find out how the human body fights diseases in John Hickey's lab.
BME Professor Charlie Gersbach is one of several researchers worldwide interviewed for an article on using CRISPR to influence gene expression by editing the epigenome with the goal of treating disease.
Sharon Gerecht and her laboratory have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel cells critical to retinal health for the first time.